• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect . Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands

tetano

Editor, Senior Moderator
J Infect


. 2025 Mar 21:106474.
doi: 10.1016/j.jinf.2025.106474. Online ahead of print. Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands

Gesa Carstens[SUP] 1 [/SUP], Eva Kozanli[SUP] 1 [/SUP], Kirsten Bulsink[SUP] 1 [/SUP], Scott McDonald[SUP] 1 [/SUP], Mansoer Elahi[SUP] 1 [/SUP], Jordy de Bakker[SUP] 1 [/SUP], Maarten Schipper[SUP] 1 [/SUP], Rianne van Gageldonk-Lafeber[SUP] 1 [/SUP], Susan van den Hof[SUP] 1 [/SUP], Albert Jan van Hoek[SUP] 2 [/SUP], Dirk Eggink[SUP] 3 [/SUP]



Affiliations
Free article Abstract

Objectives: Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity.
Methods: We collected both symptom data and nose- and throat samples from symptomatic people during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands, and tested these for 18 respiratory viruses including SARS-CoV-2. We compared reported health status, symptoms and odds of having a mono respiratory viral infection or co-infection with SARS-CoV-2 and another respiratory virus.
Results: In total 4,655 samples were included with 22% (n=1,017) testing SARS-CoV-2 positive. Of these 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses (15%; n=17) and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 - 0.24; OR: 0.21 CI 95%: 0.17 - 0.26; respectively).
Conclusions: SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and adenovirus are frequently observed in the general population, but are not associated with more severe disease compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction with rhinovirus and seasonal coronavirus, possibly decreasing risk of co-infection.

Keywords: Co-infection; SARS-CoV-2; adenovirus; disease severity; mono-infection; rhinovirus; seasonal coronavirus; viral interference; viral load.

 
Back
Top Bottom